Skip to main content

Table 1

From: Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

Best Response – D100 # Pt %
CR 1 7% (1/14)
nCR 10 72% (10/14)
VGPR 0 0
PR 3 21% (3/14)
SD 0 0
PD 0 0
Total 14 100%